EE05168B1 - N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine - Google Patents

N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine

Info

Publication number: EE05168B1
Authority: EE; Estonia
Prior art keywords: preparation; guanidinoalkamide; therapeutic use; pharmaceutical preparation; preparation containing
Prior art date: 1999-10-30

Application number

EEP200200199A

Other languages

English (en)

Inventor

Klingler Otmar

Zoller Gerhard

Defossa Elisabeth

Al-Obeidi Fahad

Walser Armin

A. Ostrem James

Original Assignee

Aventis Pharma Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-30

Filing date

2000-10-21

Publication date

2009-06-15

2000-10-21 Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh

2003-06-16 Publication of EE200200199A publication Critical patent/EE200200199A/et

2009-06-15 Publication of EE05168B1 publication Critical patent/EE05168B1/et

Links

238000000034 method Methods 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

EEP200200199A 1999-10-30 2000-10-21 N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine EE05168B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99121623A EP1095933A1 (en)	1999-10-30	1999-10-30	Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
PCT/EP2000/010395 WO2001032611A1 (en)	1999-10-30	2000-10-21	N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Publications (2)

Publication Number	Publication Date
EE200200199A EE200200199A (et)	2003-06-16
EE05168B1 true EE05168B1 (et)	2009-06-15

Family

ID=8239305

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200199A EE05168B1 (et)	1999-10-30	2000-10-21	N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine

Country Status (31)

Country	Link
US (2)	US6472562B1 (et)
EP (2)	EP1095933A1 (et)
JP (1)	JP4658430B2 (et)
KR (1)	KR100981593B1 (et)
CN (1)	CN1249026C (et)
AR (1)	AR026257A1 (et)
AT (1)	ATE264837T1 (et)
AU (1)	AU776797B2 (et)
BR (1)	BR0015186A (et)
CA (1)	CA2389412C (et)
CZ (1)	CZ301855B6 (et)
DE (1)	DE60010113T2 (et)
DK (1)	DK1228039T3 (et)
EE (1)	EE05168B1 (et)
ES (1)	ES2220553T3 (et)
HR (1)	HRP20020372B1 (et)
HU (1)	HUP0203627A3 (et)
IL (2)	IL149209A0 (et)
ME (1)	MEP54708A (et)
MX (1)	MXPA02003805A (et)
NO (1)	NO328016B1 (et)
NZ (1)	NZ518607A (et)
PL (1)	PL203859B1 (et)
PT (1)	PT1228039E (et)
RS (1)	RS50471B (et)
RU (1)	RU2253651C2 (et)
SI (1)	SI1228039T1 (et)
SK (1)	SK286856B6 (et)
TR (1)	TR200201181T2 (et)
WO (1)	WO2001032611A1 (et)
ZA (1)	ZA200203294B (et)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE501164T1 (de) *	2003-07-04	2011-03-15	Lonza Ag	Verbessertes verfahren für festphasensynthese
EP2915564B1 (en)	2007-09-28	2020-11-04	Portola Pharmaceuticals, Inc.	Antidotes for factor XA inhibitors and methods of using the same
MX2010007419A (es)	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
RU2377990C1 (ru) *	2008-07-23	2010-01-10	Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет"	Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов
MX2011004907A (es)	2008-11-14	2011-07-29	Portola Pharm Inc	Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
EP3121271B1 (en)	2009-03-30	2019-07-24	Portola Pharmaceuticals, Inc.	Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) *	2009-07-15	2017-03-16	Portola Pharmaceuticals, Inc.	Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
ES2637113T3 (es)	2011-01-10	2017-10-10	Infinity Pharmaceuticals, Inc.	Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013337717B2 (en)	2012-11-01	2018-10-25	Infinity Pharmaceuticals, Inc.	Treatment of cancers using PI3 kinase isoform modulators
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
SG11201811237WA (en)	2016-06-24	2019-01-30	Infinity Pharmaceuticals Inc	Combination therapies
CN110357800B (zh) *	2018-04-09	2022-07-26	青岛海生洋润生物科技有限公司	脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用
CN115317474A (zh) *	2021-05-10	2022-11-11	中国海洋大学	一种苯酰胍衍生物在用于制备预防和治疗神经系统疾病或心血管系统疾病的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU206372B (en) *	1990-09-03	1992-10-28	Richter Gedeon Vegyeszet	Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
US5506134A (en)	1990-10-22	1996-04-09	Corvas International, Inc.	Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5788965A (en)	1991-02-28	1998-08-04	Novo Nordisk A/S	Modified factor VII
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5371072A (en) *	1992-10-16	1994-12-06	Corvas International, Inc.	Asp-Pro-Arg α-keto-amide enzyme inhibitors
WO1994017635A1 (en)	1993-01-20	1994-08-04	Peter John Alexandrovics	A line monitoring system
DE4326465A1 (de)	1993-01-20	1995-02-09	Thomae Gmbh Dr K	Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5525623A (en) *	1993-03-12	1996-06-11	Arris Pharmaceutical Corporation	Compositions and methods for the treatment of immunomediated inflammatory disorders
EP1384725A3 (en)	1994-04-26	2007-02-21	Aventis Pharmaceuticals Inc.	Factor Xa inhibitors
ES2193202T3 (es) *	1994-12-02	2003-11-01	Yamanouchi Pharma Co Ltd	Nuevo derivado de amidinonaftilo o sal de este.
US6342504B1 (en) *	1994-12-13	2002-01-29	Corvas International, Inc.	Aromatic heterocyclic derivatives as enzyme inhibitors
KR20010023364A (ko) *	1997-08-27	2001-03-26	간자와 무츠와	3-아미디노아닐린 유도체, 활성화 혈액응고 제 ｘ 인자저해제 및 그것의 제조중간체
SE9703414D0 (sv) *	1997-09-23	1997-09-23	Astra Ab	New compounds
DK1042287T3 (da)	1997-12-24	2005-08-15	Aventis Pharma Gmbh	Indolderivater som inhibitorer af faktor Xa
WO1999037643A1 (en) *	1998-01-26	1999-07-29	Yamanouchi Pharmaceutical Co., Ltd.	Novel benzene-fused heterocyclic derivatives or salts thereof
EP0987274A1 (en)	1998-09-15	2000-03-22	Hoechst Marion Roussel Deutschland GmbH	Factor VIIa Inhibitors
CA2372079A1 (en) *	1999-05-05	2000-11-09	Aaron H. Leeman	Novel catechols as antimicrobial agents

1999
- 1999-10-30 EP EP99121623A patent/EP1095933A1/en not_active Withdrawn
2000
- 2000-10-21 ME MEP-547/08A patent/MEP54708A/xx unknown
- 2000-10-21 MX MXPA02003805A patent/MXPA02003805A/es active IP Right Grant
- 2000-10-21 JP JP2001534764A patent/JP4658430B2/ja not_active Expired - Fee Related
- 2000-10-21 DE DE60010113T patent/DE60010113T2/de not_active Expired - Lifetime
- 2000-10-21 ES ES00971396T patent/ES2220553T3/es not_active Expired - Lifetime
- 2000-10-21 RS YUP-297/02A patent/RS50471B/sr unknown
- 2000-10-21 PL PL354808A patent/PL203859B1/pl not_active IP Right Cessation
- 2000-10-21 SI SI200030422T patent/SI1228039T1/xx unknown
- 2000-10-21 NZ NZ518607A patent/NZ518607A/en not_active IP Right Cessation
- 2000-10-21 AT AT00971396T patent/ATE264837T1/de active
- 2000-10-21 AU AU10265/01A patent/AU776797B2/en not_active Ceased
- 2000-10-21 EP EP00971396A patent/EP1228039B1/en not_active Expired - Lifetime
- 2000-10-21 BR BR0015186-6A patent/BR0015186A/pt active Search and Examination
- 2000-10-21 PT PT00971396T patent/PT1228039E/pt unknown
- 2000-10-21 HU HU0203627A patent/HUP0203627A3/hu unknown
- 2000-10-21 EE EEP200200199A patent/EE05168B1/et not_active IP Right Cessation
- 2000-10-21 WO PCT/EP2000/010395 patent/WO2001032611A1/en not_active Ceased
- 2000-10-21 DK DK00971396T patent/DK1228039T3/da active
- 2000-10-21 SK SK578-2002A patent/SK286856B6/sk not_active IP Right Cessation
- 2000-10-21 CA CA002389412A patent/CA2389412C/en not_active Expired - Fee Related
- 2000-10-21 HR HR20020372A patent/HRP20020372B1/xx not_active IP Right Cessation
- 2000-10-21 IL IL14920900A patent/IL149209A0/xx active IP Right Grant
- 2000-10-21 TR TR2002/01181T patent/TR200201181T2/xx unknown
- 2000-10-21 RU RU2002114041/04A patent/RU2253651C2/ru not_active IP Right Cessation
- 2000-10-21 CN CNB008151407A patent/CN1249026C/zh not_active Expired - Fee Related
- 2000-10-21 CZ CZ20021489A patent/CZ301855B6/cs not_active IP Right Cessation
- 2000-10-26 AR ARP000105647A patent/AR026257A1/es active IP Right Grant
- 2000-10-27 US US09/697,188 patent/US6472562B1/en not_active Expired - Lifetime
2002
- 2002-04-18 IL IL149209A patent/IL149209A/en not_active IP Right Cessation
- 2002-04-25 ZA ZA200203294A patent/ZA200203294B/xx unknown
- 2002-04-29 KR KR1020027005515A patent/KR100981593B1/ko not_active Expired - Fee Related
- 2002-04-29 NO NO20022022A patent/NO328016B1/no not_active IP Right Cessation
- 2002-08-26 US US10/227,222 patent/US6664393B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CZ20021489A3 (cs)	2002-07-17
IL149209A (en)	2007-06-03
JP2003513066A (ja)	2003-04-08
US6664393B2 (en)	2003-12-16
PL354808A1 (en)	2004-02-23
CN1387508A (zh)	2002-12-25
HUP0203627A2 (hu)	2003-03-28
ES2220553T3 (es)	2004-12-16
DE60010113T2 (de)	2005-05-04
PT1228039E (pt)	2004-09-30
YU29702A (sh)	2005-06-10
HUP0203627A3 (en)	2004-12-28
SK5782002A3 (en)	2002-10-08
PL203859B1 (pl)	2009-11-30
CA2389412C (en)	2009-12-01
SI1228039T1 (en)	2004-10-31
NO20022022D0 (no)	2002-04-29
NO20022022L (no)	2002-04-29
BR0015186A (pt)	2002-07-23
CZ301855B6 (cs)	2010-07-14
HRP20020372A2 (en)	2004-08-31
KR20020047310A (ko)	2002-06-21
DE60010113D1 (de)	2004-05-27
RU2253651C2 (ru)	2005-06-10
JP4658430B2 (ja)	2011-03-23
EE200200199A (et)	2003-06-16
EP1228039A1 (en)	2002-08-07
WO2001032611A1 (en)	2001-05-10
EP1228039B1 (en)	2004-04-21
HK1050673A1 (en)	2003-07-04
NZ518607A (en)	2003-10-31
HRP20020372B1 (hr)	2011-01-31
ATE264837T1 (de)	2004-05-15
US20030162967A1 (en)	2003-08-28
SK286856B6 (sk)	2009-06-05
CA2389412A1 (en)	2001-05-10
MEP54708A (en)	2011-05-10
IL149209A0 (en)	2002-11-10
NO328016B1 (no)	2009-11-09
KR100981593B1 (ko)	2010-09-13
AU1026501A (en)	2001-05-14
MXPA02003805A (es)	2004-10-15
RS50471B (sr)	2010-03-02
RU2002114041A (ru)	2004-01-20
TR200201181T2 (tr)	2002-09-23
AR026257A1 (es)	2003-02-05
DK1228039T3 (da)	2004-08-16
US6472562B1 (en)	2002-10-29
EP1095933A1 (en)	2001-05-02
ZA200203294B (en)	2003-01-29
AU776797B2 (en)	2004-09-23
CN1249026C (zh)	2006-04-05

Legal Events

Date	Code	Title	Description
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2014-06-16	MM4A	Lapsed by not paying the annual fees	Effective date: 20131021

Publication	Publication Date	Title
EE03613B1 (et)	2002-02-15	Omeprasooli naatriumisool,selle valmistamise protsess,seda sisaldav ravimkoostis ja selle kasutamine seedetrakti häirete ravimiseks
EE200200046A (et)	2003-04-15	8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
EE05232B1 (et)	2009-12-15	Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm
EE200300587A (et)	2004-02-16	Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine
HUP0203902A3 (en)	2003-07-28	Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
EE200100684A (et)	2003-04-15	Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200100431A (et)	2002-12-16	16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE200100318A (et)	2002-10-15	Kinoliini derivaat, selle ühendi kasutamine ravimina, seda sisaldav farmatseutiline kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
EE200100480A (et)	2002-12-16	Ksenoon kasutamiseks närvimürgistuste ravis
NO20006630L (no)	2001-02-26	Farmasöytisk sammensetning for behandlingen av diabetes
EE05109B1 (et)	2008-12-15	Sulfoonamiidi derivaadid, nende kasutamine meditsiinis ning meetod nende valmistamiseks
DK1194153T3 (da)	2004-08-02	Smagsmaskerede flydende farmaceutiske formuleringer
IL156662A0 (en)	2004-01-04	Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
EE05168B1 (et)	2009-06-15	N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE200000596A (et)	2002-06-17	Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
EE04490B1 (et)	2005-06-15	Ühend, selle valmistamise meetod ning kasutamine meditsiinis
HUP0301333A3 (en)	2005-06-28	Pharmaceutical superdisintegrant, process for its preparation and its use
HUP0203597A3 (en)	2005-07-28	Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
EE200100422A (et)	2002-12-16	Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
EE200300488A (et)	2003-12-15	Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon
EE04855B1 (et)	2007-06-15	Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine
AU2003255612A8 (en)	2003-12-19	Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments
EE05175B1 (et)	2009-06-15	Asendatud bensimidasooli preparaat, meetod selle valmistamiseks ja selle kasutamine meditsiinis
EE05415B1 (et)	2011-06-15	Ravimi manustamise vahend, eriti androgeenide manustamiseks
EE04902B1 (et)	2007-10-15	Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat

EE05168B1 - N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine - Google Patents